BlackRock Inc. boosted its position in shares of Epizyme Inc (NASDAQ:EPZM) by 10.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,303,720 shares of the biopharmaceutical company’s stock after buying an additional 406,541 shares during the period. BlackRock Inc. owned approximately 0.06% of Epizyme worth $58,315,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Jennison Associates LLC boosted its stake in Epizyme by 1.7% during the second quarter. Jennison Associates LLC now owns 2,184,788 shares of the biopharmaceutical company’s stock valued at $29,604,000 after buying an additional 36,762 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Epizyme by 525.0% in the 1st quarter. Point72 Asset Management L.P. now owns 750,000 shares of the biopharmaceutical company’s stock valued at $13,313,000 after purchasing an additional 630,000 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Epizyme by 0.6% in the 1st quarter. Northern Trust Corp now owns 580,898 shares of the biopharmaceutical company’s stock valued at $10,311,000 after purchasing an additional 3,538 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Epizyme by 4.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 275,704 shares of the biopharmaceutical company’s stock valued at $3,736,000 after purchasing an additional 11,693 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Epizyme by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 225,764 shares of the biopharmaceutical company’s stock valued at $3,058,000 after purchasing an additional 6,012 shares during the last quarter. 85.06% of the stock is owned by institutional investors.

NASDAQ:EPZM opened at $9.34 on Friday. The company has a market capitalization of $736.73 million, a PE ratio of -4.28 and a beta of 1.65. Epizyme Inc has a 1 year low of $8.61 and a 1 year high of $21.40.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.11. The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $0.54 million. During the same period in the previous year, the business earned ($0.48) earnings per share. Epizyme’s revenue for the quarter was up 20.0% on a year-over-year basis. On average, sell-side analysts predict that Epizyme Inc will post -2.14 earnings per share for the current fiscal year.

In other Epizyme news, Director David M. Mott purchased 416,667 shares of Epizyme stock in a transaction dated Friday, October 5th. The shares were purchased at an average cost of $9.00 per share, for a total transaction of $3,750,003.00. Following the completion of the acquisition, the director now owns 12,088 shares in the company, valued at approximately $108,792. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 21.50% of the company’s stock.

Several equities research analysts have recently issued reports on the company. BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a research note on Thursday. SunTrust Banks raised their price objective on Epizyme to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 25th. Leerink Swann assumed coverage on Epizyme in a research note on Monday, September 24th. They issued a “market perform” rating and a $11.00 price objective for the company. Cowen reaffirmed a “buy” rating on shares of Epizyme in a research note on Monday, September 24th. Finally, Morgan Stanley assumed coverage on Epizyme in a research note on Friday, September 7th. They issued a “weight” rating for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. Epizyme currently has an average rating of “Buy” and an average price target of $21.00.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Featured Story: What is a Leveraged Buyout (LBO)?

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.